VIP treatment modulates maternal macrophage activation profile and efferocytic ability in the CBAxDBA resorption prone model

LUCILA GALLINO; GUILLERMINA CALO; VANESA HAUK; LAURA FRACCAROLI; ESTEBAN GRASSO; MONICA VERMEULEN; CLAUDIA PEREZ LEIROS; ROSANNA RAMHORST

Congreso; IV LASID Meeting LXIII Argentinean Society for Immunology Meeting II French-Argentinean Immunology Meeting; 2015

Successful embryo implantation requires a local pro‐inflammatory response subsequently shifted towards a tolerogenic one. Since VIP (vasoactive intestinal peptide) displays tolerogenic effects, we investigated whether in vivo VIP treatment contributes to an immunosuppressant localmicroenvironment associated with an improved pregnancy outcome in the CBA/J×DBA/2 resorption prone model.Implantation sites from the CBA/J×DBA/2 matings on day 8.5 of gestation were isolated after in vivo VIP treatment (2nmol/mouse i.p.) or PBS on day 6.5. VIP/VPAC, Foxp3, RORγt, TGF‐β and PPARγ expression was assessed by RT‐PCR. Peritoneal macrophages were obtained at day 8.5 andefferocytic ability was tested using latex beads‐FITC or apoptotic thymocytes and evaluated by flow cytometry and microscopy respectively. TNF‐α and IL‐12 were evaluated by ELISA on supernatans while IL‐10 by flow cytometry.Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/J×DBA/2 mating females on day 8.5 of gestation compared with non‐pregnant mice. The in vivo treatment with VIP increased the number of viable implantation sites and improved the symmetric distribution of implanted embryos (p